文献速递免疫规划

下一代减毒活黄热病疫苗在食蟹猕猴中的安全性和免疫效果评价

Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
PubMed 文献 · Vaccine · 2023-01-24

过去十年黄热病疫苗需求增加且生产用无特定病原体鸡蛋供应不足导致全球短缺。本研究在食蟹猕猴模型中评估从YF-VAX®疫苗亚株克隆、经Vero细胞无血清培养适应的新型减毒活疫苗候选株vYF的安全性和免疫原性,及强毒攻击后的保护活性。vYF耐受良好,诱导持续中和抗体和记忆B/T细胞应答,提供完全保护。

要点

  • vYF在食蟹猕猴中耐受良好,无重大安全性问题。
  • vYF诱导早期抗病毒天然免疫基因差异表达及YFV特异性IgM/IgG。
  • vYF提供对野生型YFV Asibi强毒攻击的完全保护。

核心结论

  • 非人灵长类数据提示vYF在实践上可提供至少与市售YF-17D疫苗相似的针对YFV感染的保护。

研究设计与样本

  • 在食蟹猕猴转化模型中评估vYF的安全性和免疫原性,并与已上市YF-17D疫苗比较,及评估野生型YFV Asibi强毒攻击后的保护活性。

主要发现

  • vYF耐受良好,无重大安全性问题;疫苗相关安全性观察仅限于注射部位和引流淋巴结的微小/轻微显微镜下发现,与预期免疫系统刺激一致。
  • vYF诱导早期抗病毒天然免疫相关基因差异表达,以及YFV特异性IgM和IgG抗体。
  • vYF诱导从免疫后第14天至至少第258天的高且持续YFV中和抗体滴度。
  • vYF诱导从接种后第14天至至少第221天的IgM+和IgG+记忆B细胞。
  • vYF诱导Th1干扰素(IFN)-γ和白细胞介素(IL)-2分泌效应和记忆T细胞;并提供对野生型YFV Asibi强毒攻击的有效抵抗,包括完全保护免受YFV诱导的死亡、病理、血液和肝脏可溶性生物标志物失调,以及显著降低病毒血症和病毒载量至检测限。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The increased demand for yellow fever (YF) vaccines over the last decade, along with insufficient availability of specific pathogen-free embryonated eggs required for timely vaccine production, has led to global YF vaccine shortages. A new live-attenuated YF vaccine candidate (generically referred to as vYF) cloned from a YF-VAX® vaccine (YF-17D vaccine) substrain adapted for growth in Vero cells cultured in serum-free media is currently in development. Here, we assessed the safety and immunogenicity of vYF, and its protective activity upon virulent challenge with wild-type yellow fever virus (YFV) Asibi, compared to licensed YF-17D vaccines in the translational cynomolgus macaque model. vYF was well tolerated with no major safety concerns. Vaccine-related safety observations were limited to minimal/minor microscopic findings at the injection sites and in the draining lymph nodes, consistent with expected stimulation of the immune system. vYF induced early differential expression of genes involved in antiviral innate immunity previously described in humans vaccinated with YF-17D vaccines, as well as YFV-specific IgM and IgG antibodies, high and sustained YFV neutralizing antibody titers from Day 14 up to at least Day 258 post-immunization, IgM+ and IgG+ memory B cells from Day 14 up to at least Day 221 post-vaccination, and Th1 interferon (IFN)-γ and interleukin (IL)-2 secreting effector and memory T cells. Additionally, vYF provided effective resistance to virulent challenge with wild-type YFV Asibi including complete protection against YFV-induced mortality, pathology, dysregulation of blood and liver soluble biomarkers, and a significant reduction in viremia and viral load to the limit of detection. These NHP data suggest that vYF would provide protection against YFV infection in practice, at least similar to that achieved with currently marketed YF-17D vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Piras-Douce F, Broudic K, Chautard E, et al. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques. Vaccine. 2023. PMID: 36702693. doi:10.1016/j.vaccine.2022.11.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。